Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is signi®cantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These ®ndings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.
Introduction
Class III receptor tyrosine kinases (RTKs), consisting of FLT3, c-KIT, FMS and PDGFR, share structural characteristics such as ®ve immunoglobulin-like domains in their extracellular regions and a juxtamembrane (JM) domain, a kinase domain interrupted by a kinase insert domain, and a C-terminal domain in intracellular regions (Matthews et al., 1991) . Ligand binding to the extracellular domain leads to conformational changes that induce and stabilize receptor dimerization (Weiss and Schlessinger, 1998) . The receptor dimerization brings the kinase domains into close proximity and subsequent auto-phosphorylation of tyrosine residues further increase kinase activities. Then activated RTKs phosphorylate and/or bind multiple signal molecules leading to cell proliferation, dierentiation or survival.
Several mutations of RTKs, found in human and murine malignancies, have been implicated in constitutive activation of kinases (Robertson et al., 2000) . Mutations of c-KIT in mastocytomas and gastrointestinal stromal tumors have been studied extensively at the molecular level. The mutations of c-KIT are clustered mainly in two distinct regions; missense or deletion mutations in the JM domain and missense mutations in the kinase domain (Boissan et al., 2000) . Chemical-cross linking experiments revealed that c-KIT with the former mutations underwent dimerization independent of the ligand, whereas c-KIT with the latter mutations did not (Kitayama et al., 1995) . The c-KIT JM domain reportedly exerted inhibitory eects on the receptor kinase activity (Ma et al., 1999) . However, gel-®ltration assay later showed that the missense mutation of the kinase domain also promotes the dimerization, suggesting that dimerization and phosphorylation are closely coupled (Lam et al., 1999) .
Recently, an internal tandem duplication (ITD) of the JM domain of FLT3 (FLT3/ITD) has been found in 20% of adult acute myeloid leukemia (AML) and in 3% of myelodysplastic syndrome, and is strongly associated with the leukocytosis and poor prognosis in AML patients (Horiike et al., 1997; Iwai et al., 1999; Kiyoi et al., 1997 Kiyoi et al., , 1999 Kondo et al., 1999; Meshinchi et al., 2001; Nakao et al., 1996; Rombouts et al., 2000; Xu et al., 1999; Yokota et al., 1997) . Although the duplicated sequence varied in both position and length, it is always in-frame and limited to the JM domain, resulting in an elongated product. Regardless of the sequence variety of ITD, FLT3/ITD is constitutively phosphorylated on tyrosine residues and forms homodimers and, if co-transfected with wild type (Wt)-FLT3, a heterodimer with Wt-FLT3 (Kiyoi et al., 1998) . In addition, FLT3/ITD-transfected murine IL3-dependent cell lines, such as Ba/F3, FDC-P1 and 32D, are able to proliferate without IL3 and form a blastoma when inoculated to syngeneic mice (Hayakawa et al., 2000; Mizuki et al., 2000; Zhao et al., 2000) . In FLT3, neither deletion nor missense mutations have been found in the JM domain, whereas an in-frame insertion mutant (FLT3/INS) was observed in a case with acute myeloid leukemia (Kiyoi et al., 1998) . Taken together, the JM domain seems to regulate the FLT3 kinase activation, and the elongation mutation of the JM domain might abrogate the inhibitory function for the receptor autoactivation in the absence of ligand. However, their molecular mechanisms remain unclear.
In this study, we analysed various mutant clones of the JM domain in regard to autophosphorylation and signal transduction. Furthermore, we analysed the eect of the ITD-JM domain on the receptor dimerization and phosphorylation using truncated clones lacking the kinase domain.
Results

Both elongating and shortening mutations of the FLT3 JM domain transformed 32D cells
We generated three kinds of deletion mutant FLT3 constructs whose JM domains were partially deleted (D599, deletion of codon 599; D591 ± 599; deletion from codon 591 through 599; D589 ± 599, deletion from codon 589 through 599) ( Figure 1a ). We transfected these deleted constructs into the murine IL3-dependent myeloid progenitor cell line 32D. Stable expression of mutant FLT3 was con®rmed by¯ow cytometry and Western blotting. After the cloning, the clones with the highest expression on their surface were chosen ( Figure  1b) , and used for subsequent analyses. Wt-FLT3-, FLT3/ITD-and FLT3/INS-expressing 32D cells were reported previously (Hayakawa et al., 2000; Kiyoi et al., 1998; Zhao et al., 2000) .
Each 32D cell line was washed three times with the RPMI 1640 medium containing 10% FCS, then cultured with or without IL3. Wt-FLT3-expressing 32D cells could not proliferate without IL3 as well as parental 32D cells. However, all JM-deleted FLT3 expressing 32D cells proliferated without either IL3 or FLT3-ligand (FL) (Figure 1c) , and the proliferation rates were the same as those with IL3 ( Figure 1d ). These results indicated that not only the elongating but also the shortening JM domain transformed 32D cells.
Tyrosine residues in the JM domain are not essential for the transformation of 32D cells by the length-mutated FLT3
Since the D589 ± 599 mutant FLT3 transformed 32D cells, four tyrosine residues in this region seemed not to be essential for the transformation by the mutant FLT3 whose JM domain length was modi®ed. We, further, examined the role of tyrosine residues in receptor activation by the tyrosine to phenylalanine substituted FLT3 constructs. We substituted all four tyrosine residues (Y589, Y591, Y597 and Y599) to phenylalanine in Wt-FLT3, FLT3/ITD and FLT3/INS (4F-FLT3, 4F-FLT3/ITD and 4F-FLT3/INS) ( Figure  2a ). In the 4F-FLT3/ITD, we, further, substituted four tyrosine residues, which were formed by the duplicated mutation, to phenylalanine (8F-FLT3/ITD). We transfected these constructs into 32D cells, and established stably expressed clones (Figure 2b The role of the FLT3 JM domain for receptor activation H Kiyoi et al increased number of tyrosine residues. However, it was still possible that some unrecognizable structural motif might be associated with the transformation mechanism, because both ITD-and INS-mutations occurred at the same position of the JM domain and these sequences have been naturally selected in patients with AML. Thus, we introduced the 15 bp-length tandem duplication at the beginning of JM domain, at which the ITD mutation has not been found in clinical samples, in the 4F-FLT3 construct (4F-FLT3/5'TD) ( Figure 2a ). When this was transfected into 32D cells, the stably expressing cells were also transformed (Figure 2b ± d), denying the possibility described above.
Autophosphorylation of the length-mutated FLT3 and the downstream molecules
We further examined the dierence of the transformation mechanism among the length-mutated FLT3s. First, we examined the tyrosine phosphorylation status of the length-mutated FLT3s. Although tyrosine phosphorylation of Wt-FLT3 was observed only after FL-stimulation, all length-mutated FLT3s were constitutively tyrosine phosphorylated ( Figure 3 ). Notably, 4F-FLT3/ITD, 8F-FLT3/ITD, 4F-FLT3/INS and 4F-FLT3/5'TD were also constitutively tyrosine phosphorylated, while 4F-FLT3 was not even after FLstimulation ( Figure 3 ). These tyrosine phosphorylated FLT3s revealed dimer-formation after chemical crosslinking ( Figure 3 ). Next, we examined the eects of mutant FLT3s on the signal cascade. In all transformed 32D cells, MAP kinase and STAT5a were constitutively activated consistent with our previous study in FLT3/ITDexpressing 32D cells (Figure 4 ). In addition, we demonstrated the constitutive activation of SHC, which has been reported to be activated in an FL-dependent manner (Marchetto et al., 1999) (Figure 4 ). It should be noted that in the Wt-FLT3-expressing 32D cells, the phosphorylation of STAT5a was not detected even after FL-stimulation in contrast to the FL-dependent phosphorylation of MAPK and SHC. Essential role of Figure 3 Constitutive tyrosine phosphorylation and dimer-formation of the length-mutated FLT3. Wild type and mutant FLT3s were immunoprecipitated from 32D cells, and subjected to Western blot. All length-mutated FLT3s, which transformed 32D cells, were constitutively tyrosine phosphorylated. Of note is that 4F-FLT3 was not phosphorylated even after FL-stimulation. After treatment with a chemical cross-linker, all length-mutated FLT3s constitutively formed a dimer STAT5a for FLT3-dependent signaling has been reported (Zhang et al., 2000) . In this report, activation of STAT5a after FL-stimulation has been shown using the Wt-FLT3-expressing Ba/F3 cells. However, lack of detectable phosphorylation of STAT5a after FLstimulation in the Wt-FLT3-expressing 32D cells has been also reported by the other group (Mizuki et al., 2000) . Although it remains unclear why STAT5a is not phosphorylated through the Wt-FLT3 signaling in 32D cells, this discrepancy might depend on the cell-lineage (lymphoid or myeloid) of host cells for expressing Wt-FLT3.
Role of the JM domain in receptor activation
The results obtained above suggested that the JM domain has a negative role in the autophosphorylation of Wt-FLT3 in the absence of FL, and that the tyrosine residues within the JM domain were not essential for the signal-transduction in the lengthmutated FLT3. However, it remained unclear how the ITD-JM domain participated in the receptor autoactivation. To elucidate this issue, we co-expressed Wt-FLT3 and the truncated FLT3/ITD (ITD-5'/JM-myc) or the truncated Wt-FLT3 (Wt-5'/JM-myc), which lacked kinase domains for excluding the trans-eect of kinase domains, into 32D cells (Figure 5a ). We established three kinds of 32D cell lines, which expressed both Wt-FLT3 and the ITD-5'/JM-myc or the Wt-5'/JM-myc, and the ITD-5'/JM-myc alone (Figure 5b ). Interestingly, 32D cells expressing both Wt-FLT3 and ITD-5'/JM-myc (Wt-ITD-5'/JM-myc) were transformed to proliferate without IL3, in contrast to 32D cells expressing both Wt-FLT3 and Wt-5'/JM-myc alone, which did not proliferate in the absence of IL3 (Figure 5c,d ). In the Wt/Wt-5'/JM-mycexpressing 32D cells, both Wt-FLT3 and Wt-5'/JMmyc were not phosphorylated on the tyrosine residues. Furthermore, in the ITD-5'/JM-myc-expressing cells, the product was not phosphorylated. However, in the Wt-ITD-5'/JM-myc-expressing cells, Wt-FLT3 was constitutively phosphorylated, though ITD-5'/JM-myc was not phosphorylated (Figure 5e ). In addition, we analysed the interaction of the duplicated JM domain with Wt-FLT3. After crosslinking, Wt-FLT3 and ITD-5'/JM-myc formed a hetero-complex, but not Wt-FLT3 and Wt-5'/JM-myc (Figure 5f ). Taken together, these results suggested that the ITD ± JM domain abrogates the suppressive eect of Wt-FLT3 on activation through the formation of a heterodimeric complex.
Discussion
Previously, we reported that ITD was essentially clustered in the tyrosine-rich stretch corresponding to Y589 to Y599, and ITD and INS mutations, but not deletion mutations, of the FLT3 JM domain were found in clinical samples (Kiyoi et al., 1998) . However, in-frame deletion mutations were found in the c-KIT JM domain, and in the FMA3 murine mastocytoma cell line, the JM domain of c-KIT lacks seven residues corresponding to the tyrosine-rich stretch of FLT3, resulting in receptor autophosphorylation (Tsujimura, 1996) . Therefore, we ®rst examined whether the shortening mutations in the FLT3 JM domain transformed 32D cells, and have demonstrated that mutant FLT3s whose JM domains were partially deleted (D599, D591 ± 599 and D589 ± 599) transformed 32D cells as well as did FLT3/ITD and FLT3/INS. The role of a series of residues in the c-KIT JM domain in controlling receptor phosphorylation was well examined by generating a series of mutant c-KITs with single alanine substitutions for residues Met-552 through Ile-563 (Ma et al., 1999) . This region included a putative a-helix and most of the mutated residues found in gastrointestinal stromal tumors and in mastocytomas. This work demonstrated that the Y553F mutant showed receptor autophosphorylation but that the E561A mutant impaired ligand-induced phosphorylation. The tyrosine-rich stretch of the FLT3 JM domain is predicted as a putative a-helix, though it lies downstream of the region analysed in c-KIT. It is, therefore, conceivable that the tyrosine-rich stretch exerted inhibitory eects on spontaneous phosphorylation. In addition, since several SH2-containing molecules are reportedly recruited to Tyr residues of the JM domain in other Class III RTKs, we examined the role of Tyr residues (Y589, Y591, Y597 and Y599) in the JM domain in the activation of FLT3. In Wt-FLT3, these Tyr residues were important for the FLdependent activation, because 4F-FLT3-expressing 32D cells could not proliferate with FL alone and the product was not tyrosine-phosphorylated even after FL-stimulation. However, when the length of the JM In all transformed 32D cells analysed here, mutant-FLT3 was dimerized, and MAP kinase and STAT5a were constitutively activated in accordance with our previous study in FLT3/ITD-expressing 32D cells (Hayakawa et al., 2000) . In addition, we demonstrated the constitutive activation of SHC, which has been reportedly activated by Wt-FLT3 in a FL-dependent manner (Marchetto et al., 1999) . These results indicated that signal-transduction cascades following the activation of mutant FLT3 might be the same, and that no positively regulating molecules seemed to be recruited to the tyrosine residues within the JM domain. It has been shown that several negative regulators were recruited to the activated RTKs. For instance, SHP1, one of the major phosphotyrosine phosphatases, has been shown to bind to the JM domain of the activated c-KIT and play a negative role in modulating signaling (Kozlowski et al., 1998) . Previous work demonstrated that SHP1 was neither activated nor recruited by the activated FLT3 (Zhang et al., 1999) . Recently, it was demonstrated that overexpressed SHC negatively regulated cell growth induced by FLT3 activation (Marchetto et al., 1999) . However, expressing and phosphorylation status were the same among Wt-and mutant-FLT3-transfected 32D cells.
Important questions are how the JM domain suppresses receptor autoactivation and how the length-mutated JM domain abrogates the suppression. Previous reports suggested that the mutant JM domain of c-KIT promotes dimer-formation (Furitsu et al., 1993) . However, there is a possibility that the intramolecular interaction between the JM domain and catalytic domain regulates the kinase activation. Intramolecular interactions between the JM domain and phosphatase domains have been reported in receptor protein-tyrosine phosphatase RPTPm (Feiken et al., 2000) , and it has also been demonstrated that the regulatory SH3 and SH2 domains bind to the back of the catalytic domain in the Src family kinases, resulting in the intra-molecular regulation of kinase activity (Williams et al., 1998) . In addition, c-KIT whose kinase domain is mutated has been reported to also be auto-phosphorylated and stay in a dimer-state (Lam et al., 1999; Tsujimura et al., 1999) . Accordingly, it has been unclear whether the JM domain inhibits the dimer-formation and kinase activation in a trans (intermolecular)-or cis (intramolecular)-manner (Figure 6) .
Previously, we demonstrated that FLT3/ITD formed a hetero-complex with Wt-FLT3, resulting in the tyrosine phosphorylation of Wt-FLT3 as well as FLT3-ITD (Kiyoi et al., 1998) . The present study, further, demonstrated that the truncated FLT3/ITD lacking a kinase domain physically associated with and activated co-expressing Wt-FLT3, while the Wt-JM domain did not. These ®ndings elucidated a transactivating not cis-activating role for the ITD-JM domain. In Wt-FLT3, ligand binding to the extracellular domain leads to receptor dimerization, stabilizing a conformation of the catalytic domain with the Aloop in an open conformation, and enabling transphosphorylation of the A-loop. Therefore, it is conceivable that binding of some molecules to the Wt-JM domain inhibits self-dimerization of Wt-FLT3 in the absence of FL, and the length-mutation in the JM domain results in release of the inhibitory molecules. Furthermore, it is possible that the length-mutations in the JM domain induce the conformational change within the extracellular domain of FLT3, resulting in dimer-formation. On the other hand, it has been demonstrated that molecular chaperones associate with the folding of signal-transducing proteins, such as steroid hormone receptors and protein kinases, and suppress the aggregation of non-native proteins (Buchner, 1999; Freeman and Morimoto, 1996; Mayer and Bukau, 1999; Wiech et al., 1992) . Therefore, there is a possibility that some molecules are recruited to the length-mutated JM domain, stabilizing and activating the receptor (Figure 6 ).
Materials and methods
Reagents and cells
Recombinant murine IL3 was a generous gift of Kirin Brewery Co. Ltd. (Tokyo, Japan). Recombinant human FLT3 ligand (FL) was purchased from R&D Systems (Minneapolis, MN, USA). All endonucleases were purchased from New England Biolabs (Beverly, MA, USA). Murine IL3-dependent myeloid progenitor cell line, 32D, was obtained from the RIKEN cell bank (Tsukuba, Japan) and maintained in RPMI 1640 medium (Gibco ± BRL, Gaithersburg, ND, USA) supplemented with 10% fetal calf serum (Gibco ± BRL) and 1 ng/ml murine IL3.
Construction of the FLT3 mutant
Full-length human FLT3 cDNA, kindly provided by Dr Oliver Rosnet (INSERM, France), was cloned into pGEM3Zf vector (Promega, Madison, WI, USA) at SalI and PstI sites and into pMKIT-Neo mammalian expression vector, kindly provided by Dr Toshio Kitamura (University of Tokyo, Japan), at XhoI and PstI sites. For the following cloning procedures, the A¯II restriction enzyme site, which did not alter the amino acid sequence, was introduced at nucleotide (nt) 1801 of the FLT3 cDNA cloned in the pGEM-3Zf vector using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). To construct the deletion mutants of the JM domain (D599, D591 ± 599 and D589 ± 599), we ampli®ed the region spanning the transmembrane through the JM domain by polymerase chain reaction (PR) using the forward primer (Mun I-F, 5'-CAACAATTGGTGTTTGTCTCCTCTT-3') in combination with each respective reverse primer (A¯II-D599R, 5'-TTTCT-TAAGATCTTCATATTCTCTGAAAT-3', A¯II-D591-599R, 5'-GAACTTAAGATCGAAGTACTCATTATCTG-3', and A¯II-D589-599R, 5'-AACCTTAAGATCCTCATTATCTGA-GGAGC-3'). Ampli®ed products were digested by a combination of MunI and A¯II endonucleases, separated on an agarose gel, and puri®ed with a QIAquick Gel Extraction kit (Qiagen, Chatsworth, CA, USA). A MunI/A¯II fragment of the FLT3 cDNA cloned in the pGEM-3Zf vector was replaced with the ampli®ed products. To introduce the Phe substitutions for Tyr-589, -591, -597, and -599, we ampli®ed the region from no 1637 ± 1809 by PCR using the forward primer (Mun I-F, 5'-CAACAATTGGTGTTTGTCTCCT-CTT-3') in combination with the reverse primer (A¯II-R, 5'-CCATTTGAGATCAAATTCAAAACTC-3'). Ampli®ed products were digested by a combination of MunI and A¯II endonucleases, and cloned as above. Full-length FLT3/ITD and FLT3/INS cDNA were reported previously (Kiyoi et al., 1998) . To construct 4F-FLT3/ITD and -FLT3/INS, we ampli®ed the JM-downstream region of FLT3/ITD and FLT3/INS by PCR using a reverse primer, EcoRV-R, 5'-CATGATATCTCGAGCCAATCCAAAG-3', in combination with a respective forward primer, A¯II-ITDF, 5'-TATGAATATGATCTTAAGAGCTC-3', or A¯II-INSF, 5'-GAACTTAAGGATGGGAATGGGGGGAGAA-3'. An A¯II/EcoRV fragment of the 4F mutant FLT3 cDNA cloned in the pGEM-3Zf vector was replaced with the ampli®ed products. For constructing the 8F-FLT3/ITD, site-directed mutagenesis was performed on the 4F-FLT3/ITD construct. The 15 bp-length tandem duplication at the beginning of JM domain was introduced by PCR using the primers A¯II-5'TDF, 5'-CTGCTTAAGTGTCACAAGTACAAATGTCA-CAAGTACAAAAAGC-3', and A¯II-JMR, 5'-CCACTTAA-GATCATATTCATATTCTCTGAA-3'. Ampli®ed product was cloned into the JM deletion FLT3 cDNA cloned in the pGEM-3Zf vector at the A¯II site. All mutated FLT3 cDNAs cloned in the pGEM-3Zf vector were recloned into the pMKIT-Neo vector, and were con®rmed by sequencing.
Generation of the mutation FLT3-expressing 32D cell lines 32D cells were transfected with full-length mutant FLT3 cDNAs cloned in the pMKIT-Neo vector by using TransFast (Promega), then selected with G418 (Gibco ± BRL). Expression of FLT3 products was con®rmed by¯ow cytometer (EPICS ELITE; Coulter, Hialeah, FL, USA) using an antihuman FLT3 monoclonal antibody (SF1.340; Immunotech, Marseille, France) and Western blot. We established at least ®ve mutant FLT3-expressing 32D cell lines in each construct. Among them, the most highly expressing line was chosen, and used for analyses.
Phosphorylation analysis of mutant FLT3
Each 32D cell line was serum-starved for 8 h before incubation with or without human FL at 100 ng/ml for 10 min, and harvested in lysis buer as previously described (Kiyoi et al., 1998) . Lysates were immunoprecipitated with rabbit antihuman FLT3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein G Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden). The precipitated samples were separated by SDS ± polyacrylamide gel electrophoresis, and electroblotted onto Immobilon PVDF membranes (Millipore, Bedford, MA, USA). Immunoblotting was performed with anti-phosphotyrosine antibody (4G10; Upstate Biotechnology, Lake Placid, NY, USA). The membranes were incubated with the stripping buer, then reprobed with anti-FLT3 antibody. Signals were developed by using the ECL system (Amersham Pharmacia Biotech).
Transformation analysis of mutant FLT3-expressing 32D cells
Each 32D cell line was washed three times with the RPMI 1640 medium containing 10% FCS, then cultured without IL3. The cell lines, which could proliferate without IL3, were, thereafter, maintained without IL3. For cell proliferation assay, 5610 4 cells were seeded in 24-well culture dishes with or without murine IL3, and then viable cells were counted daily by Trypan blue dye-exclusion assay. In addition, we analysed the eect of mutant FLT3 on the signal-transduction pathways. Cell lysates from each cell line were extracted as described above. Whole cell lysates were separated, electroblotted and examined as to the phosphorylation status of MAP kinase using rabbit anti-phospho MAP kinase antibody (New England Biolabs). FLT3, STAT5a and SHC proteins were immunoprecipitated with anti-FLT3 (Santa Cruz Biotechnology), anti-STAT5a (Santa Cruz Biotechnology) and anti-SHC (Transduction Laboratories, Lexington, KY, USA) antibodies, respectively, and subjected to Western blot with an anti-phosphotyrosine antibody.
Effect of the duplicated JM domain on the receptor activation
The truncated Wt and FLT3/ITD cDNAs from the amino terminus through to the end of the JM domain were ampli®ed by PCR using the primers 5' SalI-F, 5'-TCCGA-ATTCGTCGACACTAGTAACGGCCGCCAG-3' and ClaI-JMR, 5'-TGGATCGATCCATTTGAGATCA-3'. Ampli®ed products were cloned into pCDNA3.2/myc vector (Invitrogen, Carlsbad, CA, USA), and the truncated cDNAs with myc-tag were recloned into the pMKIT-Neo vector (Wt-5'/ JM-myc and ITD-5'/JM-myc). These constructs were con®rmed by sequencing. We transfected full-length Wt-FLT3 cDNA into 32D cells in combination with either Wt-5'/JMmyc or ITD-5'/JM-myc and established stable transfectants as described above. Full-length Wt-FLT3 and truncated Wtor ITD-FLT3 were precipitated from each cells by using rabbit anti-human FLT3 antibody (Santa Cruz Biotechnology) or rabbit anti-myc tag antibody (Upstate Biotechnology), respectively. Since this anti-FLT3 antibody recognize its carboxy terminus, it can not precipitate the truncated FLT3. Each precipitated sample was subjected to Western blot analyses. Interaction of the duplicated JM domain with the wild FLT3 was analysed by using the chemical cross-linking procedure. Both wild type and either Wt-5'/JM-myc-or ITD-5'/JM-myc-expressing 32D cells were lysed as described above. Cross-linking was performed by an incubation with 1 mM BS 3 (PIERCE, Rockford, IL, USA) for 2 h at 228C. The reaction was stopped by adding glycine-HCl (pH 7.5) to a ®nal concentration of 150 mM and incubating for 5 min. Sodium orthovanadate (100 mM) was included in all buers. The lysates were immunoprecipitated with rabbit anti-human FLT3 antibody (Santa Cruz Biotechnology) or rabbit antimyc tag antibody (Upstate Biotechnology) and protein G Sepharose (Amersham Pharmacia Biotech), and subjected to Western blot analysis as described above.
